Quest Diagnostics (DGX) EBITDA (2009 - 2026)

Quest Diagnostics has reported EBITDA for 18 years, with the latest figure at $459.0 million in Q2 2026.

• Quarterly EBITDA rose 4.79% year-over-year to $459.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.6 billion (up 10.51% YoY) and the FY2025 annual result came in at $1.6 billion, up 15.6% from the prior year.
• EBITDA rose to $459.0 million in Q2 2026 per DGX's latest filing, from $399.0 million in the prior quarter.
• Over five years, EBITDA peaked at $513.0 million in Q1 2022 and troughed at $135.0 million in Q4 2022.
• A 5-year average of $358.3 million and a median of $358.0 million in 2024 frame the typical range for EBITDA.
• The sharpest annual moves came in 2022 and 2023: EBITDA plunged 74.81% in 2022, then soared 97.78% in 2023.
• Over 5 years, EBITDA stood at $135.0 million in 2022, then soared by 97.78% to $267.0 million in 2023, then surged by 35.21% to $361.0 million in 2024, then gained by 6.93% to $386.0 million in 2025, then increased by 18.91% to $459.0 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered $459.0 million, $399.0 million, and $386.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.